Home LiteratureArticle Details
PMID: 1718063 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506.

Transplantation ·Vol. 52 ·No. 4 ·1991-10-00 ·Pages 590-4

Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE

Abstract

FK506 and cyclosporine were used for the prevention of acute graft-versus-host disease. Acute GVHD was induced in Lewis rats by total-body irradiation and subsequent reconstitution with allogeneic (ACI) bone marrow and spleen cells (BMTx). GVHD was assessed by both clinical and histologic parameters during the experiment duration of 60 days, and longer for selected animals. All untreated BM recipients died within 26 days from severe acute GVHD. GVHD was prevented with CsA during the period of immunosuppressive therapy, but it appeared within a few days afterward. FK506-treated BM recipients were also protected, but they had a markedly prolonged GVHD-free period after therapy was discontinued. Most such animals eventually developed GVHD but with notable exceptions. Maintenance therapy with doses of FK506 as low as 0.1 mg/kg every other day (1/20 of daily induction dose) was infallible insurance against delayed GVHD. The relevance of these findings to GVHD caused by lymphoid-containing solid organs such as the intestine was discussed.

MeSH Terms
Animals Bone Marrow Transplantation/immunology Chimera/immunology Graft vs Host Disease/pathology,prevention & control Male Rats Rats, Inbred ACI Rats, Inbred Lew Tacrolimus/therapeutic use
Chemicals
Tacrolimus
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Markus P M
Department of Surgery, University of Pittsburgh, Pennsylvania 15213.
Cai X
Ming W
Demetris A J
Fung J J
Starzl T E
References (11)
11 references, click to expand
  1. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats.
    Surgery. 1991 Aug;110(2):357-63; discussion 363-4 PMID: 1713358
  2. Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506.
    Surgery. 1991 Jul;110(1):87-98 PMID: 1714104
  3. Current status of FK 506 in liver transplantation.
    Transplant Proc. 1991 Jun;23(3):1902-5 PMID: 1712133
  4. Replacement of donor lymphoid tissue in small-bowel transplants.
    Lancet. 1991 Apr 6;337(8745):818-9 PMID: 1707470
  5. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy.
    Transplantation. 1990 Aug;50(2):186-9 PMID: 1696405
  6. FK 506: an immunosuppressant for the 1990s?
    Lancet. 1991 Jan 5;337(8732):25-7 PMID: 1702172
  7. The major histocompatibility complex of the rat.
    Transplantation. 1987 Jun;43(6):773-85 PMID: 2884761
  8. Immunogenetic analysis of rat strains with recombinations in different regions of the MHC.
    Immunogenetics. 1986;23(2):133-6 PMID: 3957412
  9. Graft-versus-host disease.
    Immunol Rev. 1985 Dec;88:193-214 PMID: 3910557
  10. Graft-versus-host disease: pathophysiological and clinical aspects.
    Annu Rev Med. 1984;35:11-24 PMID: 6372650
  11. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.
    Nature. 1979 Jul 12;280(5718):148-51 PMID: 45208
Article Info
Journal
Transplantation
Abbr.
Transplantation
ISSN
0041-1337
Published
1991-10-00
Pages
590-4
Language
English
Region
United States
NLM ID
0132144
PMCID
PMC2975544
Subset
IM
Grants
NIDDK NIH HHS · R01 DK029961-19 · United States
NIDDK NIH HHS · DK 29961 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com